Skip to content
drillr.ai
Sign up

FLGT

Fulgent Genetics, Inc.

NASDAQ · Healthcare · Medical - Diagnostics & Research · US

$19.73
+0.41%
Ask drillr
Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.5x
Market Cap
$542.88M
RSI (14)
51.3
MomentumView details →
1D Return
+0.41%
YTD Return
−25.54%
SummaryUpdated Jun 1, 2026

Fulgent Genetics, Inc. (NASDAQ:FLGT) is a California-based medical diagnostics and genetic testing company founded in 2011 and headquartered in Temple City, California. The company went public in September 2016 and has evolved from a COVID-19 testing provider during the pandemic to a comprehensive genetic testing and precision medicine company. Today, Fulgent operates three main business segments: precision diagnostics, anatomic pathology, and biopharma services, while also developing therapeutic drugs through its Fulgent Pharma division.

Ask drillr about Fulgent Genetics, Inc. →

Similar companies

China Biotech Services Holdings Limited08037.HKPrenetics Global LimitedPREAclaris Therapeutics, Inc.ACRSMyriad Genetics, Inc.MYGNYunkang Group Limited02325.HKCastle Biosciences, Inc.CSTL
Latest newsMore news →
Fulgent Genetics, Inc. reported a quarterly loss of $0.58 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.46 per share, compared to earnings of $0.07 per share a year ago.36d ago